- €3.84bn
- €4.67bn
- €1.20bn
Brief: Diasorin Obtained FDA Approval For Fully Automated Laboratory Serology Tests For Human Parvovirus B19 Igm And Human Parvovirus B19 Igg On The Liaison Xl
Europe Research Roundup: Allianz, Mercedes-Benz, Tesco
European life sciences stocks rise on strong sector momentum
Italy - Factors to watch on September 21
Italy - Factors to watch on September 3
UBS cuts Diasorin to 'sell' on expectations not reflecting competition fears
Diasorin reaffirms 2026 outlook after Q2 revenue growth
Brief: Diasorin Q2 Net Profit Adjusted €57 Million
Italy - Factors to watch on July 31
Kepler sees European Medtech recovery, starts BioMerieux at 'Buy' as top pick
Brief: Diasorin Receives Us' FDA 510(K) Clearance And Clia Waiver For Liaison Nes Group A Streptococcus (Gas) Assay
Deutsche Bank cuts Diasorin to 'sell', sees company targets as stretched
Italy - Factors to watch on June 5
Italy's DiaSorin jumps after Betaville reports possible takeover interest
Europe Research Roundup: Aj Bell, Greencore, S&U
Brief: Diasorin exec says 2026 guidance doesn't factor in prolonged Middle East war
Brief: Diasorin to reinvest cash for growth, dividends or possible M&A, chairman says
Italy's Diasorin confirms 2026 target, sees 6-8% sales growth until 2030 (updated)
Italy's Diasorin confirms 2026 guidance, sees 6-8% yearly sales growth until 2030